Tylenol maker's stock lost billions after a rumor linking the medicine to autism. Wall Street says buy the dip as one bank sees a 'major overreaction'

A chorus of Wall Street analysts beg to differ, reaffirming Kenvue’s fundamental resilience and seeing this as an opportunity to buy the dip. In notes distributed to clients Monday morning, firms such as BofA Securities and Canaccord Genuity encourag... [2792 chars]